Summit Therapeutics PLC's stock price rose significantly in pre-market trading, with an increase of 4.1%.

This positive market response stems from a lung cancer treatment drug jointly developed by the company and its Chinese partner, which has achieved remarkable results in key clinical trials. Data shows that the patient survival rate of this drug is 15 percentage points higher than that of the main competing therapies on the market. This significant advantage not only brings new hope to patients, but also greatly strengthens investors' confidence in the future commercial prospects of Summit Therapeutics. The market generally believes that this breakthrough is expected to help Summit Therapeutics gain a more favorable position in the highly competitive field of cancer treatment and may bring the company considerable market share and revenue growth.